TiGenix : to Present at Key Conferences H1 2013

february 4, 2013 TiGenix to Present at Key Conferences H1 2013 Leuven (BELGIUM) - February 4, 2013 - TiGenix (Euronext Brussels: TIG), a leader in the field of cell therapy, announced today that during the first half of 2013 the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the only approved cell therapy in Europe, and of the company's innovative proprietary allogeneic stem cell platform with programs in Phase II, and III for respectively the treatment of rheumatoid arthritis (Cx611) and perianal fistulas in Crohn's disease (Cx601). February 11-12 BIO CEO Investor Conference, The Waldorf Astoria, New York, NY, U.S. Presenter: Eduardo Bravo, CEO Date & time: Tuesday, February 12, 8:30 - 8:55 Room: Room Conrad Click here for access to live webcast (registration free, but required) Replay available 1 hour after live event; archived webcast expires May 12, 2013 February 19 8(th) Annual Stem Cell Summit, Battery Gardens, Battery Park, New York, NY, U.S. Presenter: Eduardo Bravo, CEO Date & time: Tuesday, February 19, 11:55 - 12:18 March 11-13 BIO-Europe Spring, Centre Convencions Internacional, Barcelona, Spain Attendees: Eduardo Bravo, CEO, Claudia Jiménez, Senior Director Corporate Development March 16 KBC Bolero/Flanders Bio Retail Event, KBC Tower, Ghent, Belgium Presenter: Eduardo Bravo, CEO March 19 KBC Healthcare Conference, Brussels, Belgium Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO March 23 Dag van de Belegger, KBC Private Banking, Leuven, Belgium Presenter: Wilfried Dalemans, CTO Location: Archipel Business Center Date & time: Saturday, March 23, 11:45 - 12:30 April 15-16 8th edition European Smallcap Event, Paris, France Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO April 17 BioCapital, The Grand, Amsterdam, the Netherlands Presenter: Claudia D'Augusta, CFO April 17 RegenMed Investor Day, New York, NY, U.S. Presenter: Eduardo Bravo, CEO April 22-25 BIO International Convention, McCormick Place, Chicago, Illinois, U.S. Attendee: Claudia Jimenez, Senior Director Corporate Development April 23 6(th)Annual Kempen & Co Healthcare Conference, Amsterdam, the Netherlands Attendee: Claudia D'Augusta, CFO May 21-23 World Stem Cell & Regenerative Medicine Congress, Victoria Plaza, London, UK. Presenter: Eduardo Bravo, CEO Date & time: Tuesday, May 21, 10:05 - 10:30 Title: Commercial financing: exploiting translational funding opportunities May 22-23 BioEquity Europe 2013, Stockholm, Sweden Presenter: Eduardo Bravo, CEO May 30 Knowledge for Growth, ICC Ghent, Belgium Attendee: Wilfried Dalemans, CTO For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com Claudia D'Augusta Chief Financial Officer claudia.daugusta@tigenix.com Hans Herklots hans.herklots@tigenix.com +32 16 39 60 97 About TiGenix TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com. Forward-looking information This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward- looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: TiGenix via Thomson Reuters ONE [HUG#1674895]